BioCentury

8:00 AM GMT, Mar 7, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Strategy

Daiichi's U.S. comPlexx

Although Roche has worldwide rights to Plexxikon Inc.'s PLX4032, the opportunity to jump start a U.S. commercial presence in cancer on the back of co-promotion rights is leading Daiichi Sankyo Co. Ltd. to acquire the biotech for $805 million up front.

Interim Phase III data for PLX4032 were reported in January, and Roche plans to submit marketing applications in the U.S. and Europe this year.

The deal also provides the Japanese pharma with two more clinical candidates and Plexxikon's scafforld-based discovery engine.

Glenn Gormley, Daiichi Sankyo's CSO and co-head of R&D, told BioCentury the company decided about a year ago

Read the full 977 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.